| INTRODUCTION
Renal tissue hypoxia has been proposed as a critical mediator of both acute kidney injury (AKI) and chronic kidney disease (CKD). [1] [2] [3] For example, in 1998, Fine et al 4, 5 proposed the "chronic hypoxia hypothesis" for the pathogenesis of CKD. Their argument was largely based on the proposition that tubulointerstitial injury (especially fibrosis and capillary rarefaction) is a hallmark of all progressive renal diseases and that hypoxia drives fibrogenesis in the kidney. Thus, they proposed that any insult that induces either hypoxia or tubulointerstitial injury has the potential to initiate a vicious cycle. More recently, considerable evidence has been generated to support associations between tissue hypoxia and multiple forms of CKD. However, as discussed in detail herein, direct evidence of causation is rather limited. It has also been proposed that tissue hypoxia plays a critical role in the initiation and progression of AKI. 6, 7 In hospital settings, AKI commonly occurs in sepsis, 8 and after procedures associated with temporary cessation of renal perfusion or reduced renal blood flow or oxygen delivery. Such procedures include renal transplantation, tive stress. 17 In the longer term, tissue hypoxia could contribute to the interstitial fibrosis and vascular rarefaction that characterizes progression from AKI to CKD, 18 as predicted by the chronic hypoxia hypothesis.
In this review, we critically evaluate the evidence that dysregulation of renal tissue oxygenation plays specific roles in the pathogenesis of both CKD and AKI. Thus, we focus more on the identification of the gaps in our knowledge than on the evidence supporting the roles of hypoxia. To achieve this aim, we performed a systematic review of the literature related to the potential roles of hypoxia in renal pathology. In a MEDLINE search, we used the Medical Subject Headings (MeSH) and keywords "AKI" (44509 results) or "acute renal failure" (48552 results) or "CKD" (37883 results) or "polycystic kidney disease (PKD)" (10820 results) and "hypoxia" or "anoxia" (140468), giving a combined return of 10914 results (from 1956 to November 2017). Additional articles were sourced from the references of articles obtained from the search and from an examination of articles that cited the papers identified in our search. The final analysis included only original studies with at least an abstract written in English.
With analogy to Koch's 19 postulates regarding the roles of specific bacteria in infectious disease, we propose six lines of evidence that are required in order to confirm or refute the hypothesis that renal tissue hypoxia initiates and drives the progression of CKD and AKI. These are presented below as a series of questions, which we then address in turn.
1). Is kidney disease always associated with tissue hypoxia? 2). Does tissue hypoxia drive signalling cascades that lead to tissue damage and dysfunction? 3). Does tissue hypoxia per se lead to kidney disease? 4). Does tissue hypoxia precede pathology? 5). Does tissue hypoxia colocalize with pathology? 6). Does prevention of tissue hypoxia prevent kidney disease?
| IS THE DEVELOPMENT OF KIDNEY DISEASE ALWAYS ASSOCIATED WITH TISSUE HYPOXIA?
Before directly addressing this question, we must consider the strengths and limitations of the various techniques used for the assessment of renal tissue oxygenation. These have previously been reviewed in detail. 20, 21 In brief, polarographic electrodes such as the Clark-type electrode can directly quantify tissue oxygen tension (PO 2 23 This technique has been relatively well validated for the detection of cellular hypoxia in cultured tumour cells that were <10 mmHg. 24 Caveats that should be applied to this method include that it can only be applied at discrete time-points, is not quantitative and can be confounded by false-positive staining in the injured kidney, 25 and in other tissues under relatively welloxygenated conditions. 26, 27 Blood oxygen level-dependent magnetic resonance imaging (BOLD-MRI) is non-invasive and can be used in experimental and clinical settings over multiple time-points. Thus, BOLD-MRI has the potential to characterize the evolution of renal hypoxia during the development of kidney disease. Its major limitation arises from the fact that it provides a measure of the ratio of deoxyhaemoglobin to oxyhaemoglobin in the blood 28 and thus only provides a semi-quantitative and indirect measurement of tissue PO 2 . Similar to BOLD-MRI, electron paramagnetic resonance utilizes the paramagnetic nature of oxygen to attenuate magnetic resonance. This method requires the invasive implantation of a paramagnetic probe into the tissue of interest. 29 Once implanted, it allows for the direct quantification of tissue PO 2 over extended periods non-invasively 30 and thus potentially allows for determination of the temporal relationship between tissue hypoxia in the pathogenesis of kidney diseases. Assessment of the expression of hypoxia-inducible factors (HIF) and their downstream targets provides information regarding the cellular responses to hypoxia rather than hypoxia itself, which likely vary depending on physiological and pathological conditions. 31 Most recently, methods have been described that allow continuous measurement of renal tissue PO 2 in unanaesthetized experimental animals. [32] [33] [34] [35] These techniques promise to deliver exquisite temporal resolution of kidney oxygenation in both small and large animal models of kidney disease. However, they are yet to be widely employed to study models of kidney disease.
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| Chronic kidney disease
Chronic kidney disease is a complex and multifactorial disease often complicated by comorbidities such as diabetes and hypertension. However, despite the seemingly varying underlying aetiology across different forms of CKD, tissue hypoxia almost always develops at some stage during progression of the disease (Figure 1 ).
Polycystic kidney disease, the most common genetic form of CKD, is characterized by excessive and uncontrolled tubular epithelial proliferation resulting in the formation of fluid-filled cysts 39 and thus renomegaly. 40 The increased total kidney volume, in conjunction with increased angiogenesis, results in flattened and tortuous capillaries and arterioles. 41 Vascular remodelling and the expansion of the tubules in PKD not only has the potential to decrease tissue perfusion, it also has the potential to increase the distance over which oxygen must diffuse to reach renal tissue. There is also evidence that oxygen demand, at least in proportion to the level of sodium reabsorption, is augmented in PKD. 42 Thus, both decreased oxygen supply to the tissue and inappropriately high oxygen consumption likely contribute to the severe tissue hypoxia that has been observed using both quantitative ( Figure 1A ) 42 and qualitative 43, 44 methods.
Systemic lupus erythematous is a polygenic autoimmune disorder of non-cystic nature characterized by the presence of antinuclear antibodies indicative of an aberrant immune response to autoantigens. 45 In lupus nephritis (LN), inflammatory cytokines mediate fibrogenesis. 46 The resultant expansion of extracellular matrix could promote tissue hypoxia by increasing the distance for diffusion of oxygen to tissue. Deng et al 47 showed the upregulation of glomerular hypoxia-inducible factor 1-a (HIF-1a) in renal biopsies obtained from patients with LN. HIF-1a expression was positively correlated with severity of the disease and proliferative index in LN. 47 Critically, the expression of HIF-1a
can be upregulated in the presence of IL-6, even under normoxic conditions, suggestive of molecular crosstalk between inflammatory mediators and induction of HIFs. 48 However, we are not aware of studies in which renal oxygenation has been examined in LN using more direct methods. Cellular 49 and tissue 50, 51 hypoxia in the kidney is a common finding in animal models of diabetic nephropathy. Treatment with insulin abolished cellular hypoxia, suggesting that the hypoxia is dependent on hyperglycaemia. 49 Extending these observations to the clinical setting, several studies using BOLD-MRI have provided evidence of hypoxia in the cortex and medulla in patients with diabetic nephropathy. 52, 53 In contrast, using the same technique, Wang et al 54 could not detect differences in the BOLD signal in the renal cortex of patients with diabetic nephropathy compared to healthy volunteers ( Figure 1B) . Indeed, the medulla actually appeared to be better oxygenated in patients with diabetic nephropathy than in controls. 54 Additionally, renal hypoxia was also not detected in a recent BOLD-MRI study of patients with CKD, inclusive of patients with diabetic nephropathy. 55 The discrepancies in these clinical observations may be due to (i) the relative sensitivity of the BOLD-MRI technique to changes in tissue oxygenation per se and/or (ii) differences in the severity of CKD in the populations included in the various studies. Importantly, the disparity in observations using BOLD-MRI in human diabetic nephropathy indicates that the relationship between tissue hypoxia and progression of the disease is likely complex. The absence of tissue hypoxia during any particular stage cannot rule out a pathogenic role during an earlier or later stage. On the other hand, the presence of hypoxia, even if throughout the natural history of kidney disease, does not provide evidence that hypoxia contributes mechanistically to the development of diabetic nephropathy.
Reduction in renal mass reduces the number of viable nephrons, resulting in compensatory increases in single nephron glomerular filtration rate (GFR). 56 The increase in single nephron GFR appears to drive increased oxygen consumption in the remaining viable nephrons. 56, 57 This, and other factors such as fibrosis 58, 59 and oxidative stress, 60, 61 may drive the development of tubulointerstitial hypoxia ( Figure 1D ). In these so-called remnant kidney models, hypoxia has been observed in both the cortex [61] [62] [63] and medulla. 62 In contrast, Priyadarshi et al 64 observed that cortical and medullary tissue PO 2 was greater, 6-8 weeks following renal mass reduction. The discrepancy between these observations may be related to the time-course of progression of the disease. That is, tissue hypoxia may be important in the acute and subacute phases following reduction in renal mass, but not in the longer term. Nevertheless, the balance of evidence suggests that tissue hypoxia is a characteristic of the remnant kidney model. In renovascular disease, once the narrowing of the main renal artery or its proximal branches reaches a critical stage, marked reductions in renal blood flow occur. 65 Examination of renal tissue oxygenation in animal models of renovascular disease has yielded conflicting results, likely due to differences in severity and the time-course of progression of the disease. Palm et al found, in a rat model of renovascular disease, that cortical hypoxia developed 3 weeks after stenosis and was accompanied by a reduction in renal blood flow. 66, 67 In contrast, Rognant et al, 68 using BOLD-MRI, found that renal blood oxygenation changed little in the 4 weeks following stenosis. In the clinical setting, patients with renovascular disease had rather well-oxygenated renal blood in comparison with the contralateral kidney, despite reductions in cortical and medullary blood flow. [69] [70] [71] However, it appears that cortical hypoxia may develop once the stenosis reaches a critical level (>70%) so that cortical blood flow is markedly reduced. 72 The explanation for these disparate findings may lie in the effect of a stenosis on the balance between oxygen delivery and oxygen demand. Importantly, reductions in GFR induced by a stenosis should act to reduce renal oxygen demand for sodium reabsorption and so reduce the risk of renal hypoxia. 6 In summary, renal hypoxia is a common, but not universal, characteristic of CKD. It is also relevant here to consider recent evidence that interstitial fibrosis, microvascular dysfunction and capillary rarefaction are characteristics of CKD, regardless of its aetiology. 73 
| Acute kidney injury
Acute kidney injury is associated with increased morbidity, increased length of stay in hospital in the case of hospitalacquired AKI and increased risk of death. 74 Furthermore, patients who recover from AKI are at increased risk of development of CKD and end-stage renal disease. 75, 76 Evidence of renal tissue hypoxia has been observed in multiple forms of AKI ( Figure 2 ). Ischaemia-reperfusion injury (IRI) is the leading cause of AKI in the hospital setting. 77 Flow to the kidney is temporarily occluded during surgical procedures such as renal transplantation (cold ischaemia), or resection of a renal tumour or reparation of an abdominal aneurysm (warm ischaemia). Consequentially, oxygen delivery to the kidney ceases and the kidney becomes anoxic. Following reperfusion, the kidney, particularly the medulla, has been observed to be hypoperfused. 78 Hypoperfusion is likely driven by multiple factors, including capillary obstruction resulting from infiltration of immune cells, vasoconstriction and loss of endothelial integrity. 15, 79, 80 Hypoperfusion following reperfusion compromises renal oxygen delivery 25, 78, 81, 82 and thus promotes tissue hypoxia. 78, [82] [83] [84] [85] Cardiac surgery, particularly when requiring cardiopulmonary bypass (CPB), is a major cause of AKI. 86 Ischaemia and reperfusion injury likely make an important contribution to the pathophysiology of AKI in this setting. Renal oxygen delivery is decreased by~20% during CPB in humans. 86 However, renal oxygenation during CPB has only been measured directly in experimental animals. Stafford-Smith et al, using a blood gas probe, examined medullary oxygen tension in a porcine model of CPB. They found that 30 minutes into CPB, medullary PO 2 was markedly reduced. 87 Medullary hypoxia in these pigs did not appear to recover 30 minutes post-CPB, 87 suggesting the presence of persistent medullary hypoxia after CPB. Medullary hypoxia was also observed to develop in rats during CPB and was augmented by anaemia. 88 Mathematical models have also predicted that haemodynamic conditions associated with CPB, including haemodilution and hypotension, render the medulla susceptible to hypoxia. 89, 90 Renal hypoxia in AKI that occurs after CPB might be associated with abnormalities in both renal oxygen delivery and consumption. In a prospective study, Redfors et al compared renal oxygen delivery and consumption in patients with AKI relative to those with normal postoperative renal function following cardiac surgery requiring CPB. They demonstrated that renal blood flow (~40%) and hence renal oxygen delivery were markedly reduced in patients with AKI compared to those without AKI. 91 GFR and hence tubular sodium reabsorption were also greatly decreased. Interestingly, the reduction in tubular workload had no detectable effect on renal oxygen consumption. 91 This may be indicative of inefficient oxygen utilization for sodium reabsorption in AKI, which could be an important contributor to renal tissue hypoxia. Renal tissue hypoxia has also been observed after CPB in experimental animals. 87, 88, 92 In pigs, Patel et al 92 found that 24 hours after CPB, total renal blood flow was decreased and the medulla was hypoxic. Taken collectively, these experimental and modelling studies provide evidence for medullary hypoxia during and after CPB. Administration of iodinated contrast agents can lead to AKI. 93 Medullary hypoxia has been consistently observed in animals administered contrast agents. [94] [95] [96] [97] [98] Furthermore, administration of contrast agents was associated with increased deoxyhaemoglobin content in the medulla of healthy human subjects. 99 The mechanisms mediating medullary hypoxia after contrast administration remain to be definitively established. Contrast agents have been shown to promote constriction of vasa recta, at least in part ; (D) 84 with permission due to endothelial dysfunction. 93 Tubular dilation associated with contrast administration may also promote compression of vasa recta. 93 Increased tubular sodium reabsorption, and thus oxygen consumption, could also play a role. 93 Thus, renal tissue hypoxia may contribute to the pathogenesis of contrast-induced nephropathy, However, other factors are also likely to be important, including direct toxic effects of contrast agents 100 and their propensity to increase intratubular pressure secondary to their viscosity (reviewed in 93 ).
Sepsis is one of the most common causes of AKI in the intensive care unit (ICU), with an incidence of 10%-48% in the ICU. 101 The mortality rate for septic AKI of~70% is considerably greater than AKI of non-septic nature (~45%) 102 or sepsis alone (~35%). 103 Rodent models of septic AKI are characterized by global vasoconstriction and consequently renal hypoperfusion. 104 But sepsis in these models is most commonly induced by infusion of lipopolysaccharide (LPS), a component of the outer surface membrane of gram-negative bacteria, resulting in systemic inflammation and ultimately renal vasoconstriction. 105 In LPS-induced septic AKI, renal blood flow is markedly reduced, so it is unsurprising that renal hypoxia has been observed in this setting using multiple methods. strated selective ischaemia and hypoxia in the renal medulla, despite systemic and global renal hyperaemia and well-maintained cortical perfusion and oxygenation. Thus, even in the absence of global renal ischaemia, hypoxia in the renal medulla appears to be a common characteristic of septic AKI. In summary, renal hypoxia, particularly in the medulla, appears to be a common characteristic of AKI. However, in both AKI and CKD, the presence of hypoxia does not necessarily show it has pathophysiological roles. Below, we turn our attention more specifically to the issue of causation.
| DOES TISSUE HYPOXIA DRIVE SIGNALLING CASCADES THAT LEAD TO TISSUE DAMAGE AND DYSFUNCTION?
Upregulation of HIFs has been observed in multiple forms of kidney disease in both humans 47, 83, 113, 114 and experimental animals. 115, 116 HIFs are heterodimeric transcription factors consisting of an oxygen-sensitive a subunit and a constitutively expressed b subunit. 117 In response to hypoxia, the a subunit is stabilized and subsequently translocates to the nucleus. Dimerization of the a and b subunits results in the downstream transcription of hypoxia-responsive elements. 117, 118 There are many known HIF target genes, including but not limited to EPO, VEGF, TGF-b, ET-1, MMP, NOS2 and Bcl-2. Hence, HIFs have complex effects on cellular activities (Table 1) . 119, 120 The downstream activation of hypoxia response genes in response to the activation of HIFs can be beneficial in some cases, but deleterious in others. 121 
| HIFs and erythropoietin
Erythropoietin, transcribed from the EPO gene, is the master regulator for the production of erythrocytes. 122 HIF is the key factor that directs transcription of the EPO gene within peritubular fibroblasts in the kidney. 123 Thus, arterial hypoxaemia and/or anaemia cause renal hypoxia, 6 and thus increased synthesis and release of erythropoietin.
122
The general consensus is that, during a hypoxic event, the stabilization of HIF-2a results in the transcription of EPO and the subsequent production of erythrocytes. 124, 125 The importance of this pathway is further highlighted by the observation that mutations in HIFs themselves, or factors involved in stabilization/degradation of HIFs, often result in erythrocytosis. 123 Further to its role in the production of red blood cells, it appears that erythropoietin may modulate tissue injury after an ischaemic event by exerting anti-apoptotic 126, 127 and anti-inflammatory 128 effects. It thus appears that hypoxia-induced production of erythropoietin may be renoprotective. However, there is emerging evidence of deleterious outcomes in the longer term that may contribute to worsening/predisposition to CKD. For example, Gobe et al 129 recently found that administration of recombinant human erythropoietin at the time of reperfusion after ischaemia exacerbated the later development of renal fibrosis. Taken together, the available data indicate that erythropoietin may be an effective treatment during the acute phase of IRI but may contribute to development of CKD in the longer term.
| HIFs and fibrogenesis
Fibrosis and associated microvascular rarefaction is a hallmark of CKD. 73 Together, these phenomena are predicted to impede the diffusion of oxygen into renal tissue, thus exacerbating hypoxia. 5 There is a delicate balance between the production of extracellular matrix (ECM) and its destruction. In response to tissue hypoxia in vitro, expression of genes for the production of collagen, Coll-1 and TGF-b, increases. [130] [131] [132] There is also upregulation of the other constituents of the 6 of 18 | ECM such as fibronectin. 133 The profibrotic matrix metalloproteinases (MMPs) such as MMP-9 and MMP-2, whose production is regulated by the activity of transforming growth factor b (TGF-b), can degrade the basement membrane. 134 This may in turn result in a chemotactic response, attracting neutrophils and macrophages. 135 The influx of immune complexes may ultimately result in the remodelling of the ECM, so contributing to the pathology of various kidney diseases. 136 The activity of MMP inhibitors, the TIMPs, has been reported to increase in kidney diseases. 136 It appears that the activities of TIMP-1 and TIMP-2 increase in response to hypoxic conditions, in association with increased TGF-b and Coll-1. 137 Thus, hypoxia-dependent stabilization of HIF-1a and consequent translation of downstream genes that promote fibrogenesis may be a critical pathogenic event in the progression of CKD.
| HIFs and the innate immune system
The activation (or overactivation) of the innate immune system, and its priming for the activation of the adaptive immune system following injury, may be detrimental to the cell. 79 Rama et al 138 found that exposure of immature dendritic cells to hypoxia (0.5% O 2 ) resulted in their differentiation and maturation, which was associated with a threefold increase in HIF-1a mRNA. This observation suggests that the activation of innate immunity may be dependent on hypoxia-induced stabilization of HIF-1a. 138 Furthermore, HIF-1a activation in response to hypoxia results in the upregulation of translation of mRNA for Toll-like receptors 2 and 6 on human dendritic cells, ultimately resulting in the production of the pro-inflammatory cytokine interleukin-6. 139 In response to the oxygen-starved cellular environment, neutrophils are upregulated by HIF-1a-dependent regulation of nuclear factor (NF)-jB. 140, 141 On the other hand, the accumulation of macrophages at sites of tissue injury, under hypoxic conditions, increases the gene expression of numerous proangiogenic, pro-inflammatory, cytotoxic and immunosuppressive factors. 142 The expression of these immune complexes can in turn be modulated through the stabilization of HIF-1a in hypoxic conditions. Thus, the activation of innate immunity during hypoxia has a wide range of downstream effects including mechanical plugging of the vasculature by immune cells, possibly further compromising blood flow. Consequentially, further recruitment of immune cells may result in propagative tissue injury and deranged cellular integrity. 143, 144 One of the caveats to consider with regard to the observations described above is that many of these studies were performed under in vitro conditions. As such, immortalized cells are often used and they may not mimic the normal physiology of renal cells in vivo. Furthermore, cultured cells may adapt to incubation conditions, so may respond to stimuli in a different manner to the cellular response in vivo. Therefore, it is imperative that we extend these studies to in vivo conditions that closely represent the physiological adaptations and responses to hypoxic conditions. One way that we can examine the role of the activation of HIFs and its contribution to the maladaptive responses to IRI in vivo is through imaging studies. The improvements in multiphoton imaging in recent years have greatly improved our ability to image the kidney in living, albeit anaesthetized, rodents. 145, 146 It is now possible to simultaneously examine multiple physiological parameters such as blood flow, 147 mitochondrial energetics, 148 oxidative stress 149 and leucocyte activity 150 in vivo. Harnessing the advantages of this imaging technique, one could examine the involvement of HIFs by examining these parameters in renal disease using multiphoton imaging in models of HIF knockout, HIF inhibition or HIF activation. One limitation of this method is that, because of the limitation in tissue penetration of the light source, imaging of the kidney is often restricted to the renal cortex. 151 Nevertheless, the combination of multiphoton imaging and models of altered HIF activity might shed more light on the role of HIFs in the initiation and progression of kidney disease.
| HIFs, VEGF and angiogenesis
The relationships between VEGF, HIF and capillary angiogenesis are likely complex. There are indeed many reports documenting close correlation between microvascular rarefaction and tissue hypoxia. 62, 152 VEGF is one of the many HIF-induced target genes. Tissue hypoxia as a result of microvascular rarefaction might be expected to upregulate HIF and thus VEGF, thereby reversing microvascular loss. Indeed, expression of VEGF was shown to be strongly induced in cultured proximal tubular epithelial cells 153 and human epithelial cells 154 exposed to hypoxia. Furthermore, TGF-b and hypoxia appear to act independently and synergistically to upregulate VEGF. 153 But VEGF can be downregulated in CKD. For example, in murine adriamycin nephrosis, expression of VEGFA was found to be reduced despite induction of HIF-1. 155 Furthermore, in a remnant kidney model, Kang et al 156 found peritubular capillary rarefaction was associated with decreased VEGF expression. VEGF administration in this model reduced renal fibrosis and stabilized renal function. 157 Treatment with VEGF-121, given at the time of reperfusion, also ameliorated capillary rarefaction in the chronic phase of IRI. 158 On the other hand, upregulation of VEGF in the tubules of adult mice led to fibrosis, cyst formation and glomerular hypertrophy, along with proliferation of peritubular capillaries. 159 Thus, VEGF remains an attractive target to combat hypoxia-induced microvasculature loss, but off-target effects may limit its utility.
| Protective effects of HIF activation
Given the potential beneficial effects of HIF activation on renal pathology, upregulation of HIF abundance by inhibition of prolyl hydroxylase domain-containing protein (PHD), which mediates degradation of HIF-1a, is an attractive therapeutic target. However, these therapies have had mixed success. It seems that the effectiveness of PHD inhibition depends critically on the time at which interventions are given during the course of disease, and also on the specific pathological features of the renal disease in question.
In terms of AKI, Bernhardt et al 160 demonstrated amelioration of graft injury and improved survival in a rat model of allogenic renal transplant, by prophylactic treatment of donor rats with the PHD inhibitor FG-4497. The same group demonstrated amelioration of renal IRI by prophylactic treatment with FG-4497 or 2-(1-chloro-4-hydroxyisoquinoline-3-carboxamido) acetate (ICA). 161 However, PHD inhibition was not effective when given after the ischaemic insult. 162 In terms of CKD, Nordquist et al 163 found that upregulation of HIFs by chronic treatment with cobalt chloride blunted diabetic nephropathy in rats. It also ameliorated renal hypermetabolism and renal tissue hypoxia. Cobalt chloride also inhibited tubulointerstitial injury in Thy1 nephropathy. 164 There is also some evidence that HIF activation can blunt progression from AKI to CKD, as reviewed by Tanaka et al 164 However, in a model of hypertension and CKD induced by blockade of nitric oxide synthase and a high salt diet, the PHD inhibitor dimethyloxallyl glycine exacerbated hypertension and urinary protein excretion. 165 
| DOES TISSUE HYPOXIA PER SE LEAD TO KIDNEY DISEASE?
The available evidence relating to this question is scarce. Friederich-Persson et al 166, 167 used the mitochondrial uncoupler 2,4-dinitrophenol and the thyroid hormone triiodothyronine to induce tissue hypoxia by increasing renal oxygen consumption independent of tubular workload. Chronic treatment of rats with either 2,4-dinitrophenol or triiodothyronine resulted in increased renal oxygen consumption ( Figure 3A ) and renal tissue hypoxia ( Figure 3B ). 166, 167 Interestingly, tissue hypoxia in this model was associated with proteinuria ( Figure 3C ). 166, 167 Additionally, they found that renal tissue hypoxia induced by treatment with 2,4-dintrophenol was associated with nephropathy even in the absence of confounding factors such as diabetes, hypertension, oxidative stress or tubular damage. 167 Thus, chronic tissue hypoxia per se may drive tissue injury independent of traditional risk factors for CKD. Arguably, these studies provide the strongest available evidence for a causative role of tissue hypoxia in CKD.
A major impediment to further progress in our understanding of the role of tissue hypoxia in the development of kidney disease relates to the nature of the models we study. Most experimental methods for inducing kidney disease inevitably also induce tissue hypoxia. For example, in IRI, blood flow, and thus oxygen delivery to the kidney, temporarily ceases. Similarly, removal of 5/6th of renal mass results in hyperfiltration and thus presumably increased oxygen consumption by individual tubules. 56 Along the same lines, CKD is often accompanied by the development of anaemia. 168 Anaemia, in turn, reduces renal oxygen delivery and promotes renal tissue hypoxia. Nevertheless, correction of anaemia by erythropoietin therapy has not been shown to delay progression of CKD. 169 Thus, it is often hard to delineate whether tissue hypoxia is a cause or consequence, or both, of the kidney disease. New experimental models of kidney disease, and new methods to follow the temporal and spatial relationships between hypoxia and renal damage, are required to overcome this limitation.
| DOES TISSUE HYPOXIA PRECEDE PATHOLOGY?
One of the important factors to consider for the development of therapeutic interventions to mitigate renal tissue hypoxia (discussed later in detail) is the timing of the intervention. Thus, it would be valuable to assess the time-course of development of tissue hypoxia relative to tissue injury.
Traditional and emerging biomarkers of AKI and CKD such as kidney injury molecule-1, neutral gelatinase-associated lipocalin and cystatin C are markers of kidney injury. Thus, if hypoxia causes kidney injury, we would expect hypoxia to precede the increased expression of these molecules. Unfortunately, to the best of our knowledge, there have been no reports of the temporal relationship between the onset of tissue hypoxia and the earliest time-point where upregulation of markers of kidney damage can be detected.
Due to the highly invasive nature of most methods for the direct assessment of tissue oxygenation in animal models of kidney disease, renal tissue oxygenation is often only assessed at single time-points, providing only "snapshots" of the natural progression of disease. Recently, this technical limitation has been addressed through development of new methods.
Electron paramagnetic resonance oximetry provides a partial solution to the limitation described above. Franzen et al 50 recently used this technique to demonstrate tissue hypoxia as early as 3 days after induction of type 1 diabetes that was sustained for at least 15 days ( Figure 4A ). Critically, tissue hypoxia in this model of type 1 diabetes was evident before the onset of significant albuminuria ( Figure 4B) . A telemetric method has been developed for use in unrestrained rats that allows continuous measurement of renal tissue oxygen tension via the electrochemical reduction of oxygen at the tip of an implanted carbon paste electrode. 34, 35 Using this technique, Emans et al 37 found that cortical tissue hypoxia developed 15 hours after the activation of the endogenous renin-angiotensin system in Cyp1a1Ren2 transgenic rats, a model of angiotensin II-dependent hypertensive CKD. Importantly, tissue hypoxia in this model of CKD was present well before the development of renal damage, consistent with the proposition that renal hypoxia could contribute to CKD induced by activation of the renin-angiotensin system. 171, 172 Calzavacca et al 33 used chronically implantable fibreoptic probes to investigate the time-course of development of tissue hypoxia in an ovine model of sepsis. In conscious sheep, they demonstrated reduced medullary tissue perfusion and PO 2 in response to infusion of live bacteria ( Figure 4C ). 36 Critically, medullary hypoxia developed before overt changes in creatinine clearance occurred (Figure 4D) , suggesting that medullary hypoxia precedes the development of renal dysfunction in this model of AKI. 36 The recent observations described above, using techniques that allow long-term measurement of renal tissue PO 2 , are consistent with the hypothesis that tissue hypoxia is a driver of pathophysiology of various forms of kidney disease. However, they do not yet constitute a "smoking gun." 173 There is considerable scope for further use of these methods to generate more detailed information regarding the temporal relationships between hypoxia, the molecular drivers of kidney disease, and renal damage and dysfunction. However, we also require information regarding the spatial relationship between tissue hypoxia and renal pathology, and most of all, on the efficacy of treatments for AKI and CKD that target renal hypoxia. To better characterize the role of tissue hypoxia in kidney damage and dysfunction, we require a better understanding of the spatial relationships between tissue hypoxia and tissue damage. Of the many methods available for the examination of tissue hypoxia, most either have limited spatial resolution or are indirect indicators of tissue hypoxia. 20 One method that overcomes the lack of spatial resolution is pimonidazole adduct immunohistochemistry. However, this method is not without limitations. Pimonidazole, a 2-nitroimidazole, has been used extensively in studies of tumour biology. 174, 175 Pimonidazole is given in vivo and forms adducts in tissues where the oxygen tension is <10 mmHg. 24 These adducts can be detected by immunohistochemistry once the tissue of interest is excised. 176 Thus, this method does not allow quantification of the severity of tissue hypoxia. An additional caveat is that upregulation of some nitroreductases may lead to deposition of pimonidazole adducts even under normoxic conditions. 27 Furthermore, the potential for detection of hypoxia in the renal cortex is rather limited as tissue PO 2 is probably rarely <10 mmHg in viable cortical tissue. On the other hand, this method provides excellent spatial resolution. Despite the limitations of pimonidazole adduct immunohistochemistry, it is currently the only available direct marker of cellular hypoxia in the kidney. This method was adapted for use in the kidney and was optimized by Rosenberger et al. 176 Since then, it has been used to demonstrate renal tissue hypoxia in many studies where direct quantification of tissue PO 2 is not available/not feasible. Indeed, Rosenberger et al 177 observed the colocalization of pimonidazole adducts and HIF-1a in the medulla but not in the cortex in a model of contrast-induced nephropathy ( Figure 5 ). This suggests that the tissue hypoxia arising from administration of radiocontrast agents is associated with downstream activation of HIF-dependent signalling pathways.
To better characterize the spatial relationships between tissue hypoxia and tissue injury in kidney disease, it should be possible to stain serial sections of kidney tissue for pimonidazole adducts and markers for tissue injury. It should also be possible to tag pimonidazole adducts and markers of tissue injury with fluorophores to compare their localization in three-dimensional rendering of fluorescence imaging. Some markers of interest that may indicate tissue damage are periodic acid-Schiff stain, Masson's trichrome, vimentin, CD31 and CD34.
| DOES PREVENTION OF TISSUE
HYPOXIA PREVENT KIDNEY DISEASE?
If indeed tissue hypoxia is the critical driver of kidney diseases, then abrogation of hypoxia should delay the progression of, or even prevent, kidney disease. Unfortunately, there are currently few therapeutic options for abrogating tissue hypoxia. One proposed therapy is normobaric or hyperbaric hyperoxia, which could increase renal oxygen delivery. Normobaric hyperoxic treatment in a rat model of haemorrhagic shock reduced renal tubular damage and abrogated cellular hypoxia, although it did appear to exacerbate renal oxidative stress. 178 Hyperbaric hyperoxia, applied in a rat model of sepsis, markedly reduced tubular and glomerular damage but did not result in oxidative stress. 179 Thus, there is scope to further explore the potential benefits of this approach. But, critically, observations F I G U R E 5 Evidence of colocalization of tissue hypoxia and pathology. Shown are serial sections of renal medullary tissue from a rat with contrast-induced nephropathy. The serial sections were stained with (A) haematoxylin and eosin, (B) hypoxia-inducible factor-1a (HIF-1a) and (C) pimonidazole adducts. HIF-1a present in tubules was colocalized with areas of moderate (blue asterisk and circle) and extensive (red asterisk and circle) staining of pimonidazole adducts but not in areas where there was absence of pimonidazole adducts (black asterisk and circle). Images were reproduced from Ref. 177 with permission in most of these studies were generated in animal models that may not necessarily reflect kidney disease in humans. Therefore, the next step might be phase 1 and phase 2 clinical trials of normobaric/hyperbaric hyperoxia in patients with certain forms of AKI or even CKD. The acute effects of normobaric hyperoxia on cardiovascular function in patients with CKD have been assessed, but have generated rather conflicting findings. Hering et al 180 subjected patients with CKD to brief normobaric hyperoxia. They showed that the abnormally high muscle sympathetic nerve activity was significantly attenuated following 15 minutes of exposure to passive breathing of 100% O 2 . 180 In contrast, van der Bel et al 181 reported
increases in systemic vascular resistance in response to normobaric hyperoxia. Thus, it seems likely that the cardiovascular response to hyperoxia depends on the balance of changes in chemoreflex (reduced sympathetic vasomotor drive) and local (vasoconstrictor) control of the circulation. The question of whether hyperoxia can ameliorate AKI or delay the progression of CKD remains to be determined. Such longer-term trials might be problematic, given the established toxic effects of oxygen.
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Aside from increasing renal oxygen delivery, the alternative approach to abrogating tissue hypoxia is by reducing renal oxygen consumption. Indeed, inhibition of tubular reabsorption may improve medullary tissue oxygenation 183 and reduce renal damage. 184 For example, the diuretic furosemide has also been shown to abrogate renal damage and dysfunction in a rat model of contrast-induced nephropathy. 185 It is also possible that the beneficial effects of protein restriction on progression of CKD 186 could at least be partly mediated by improved oxygenation of the renal outer medulla. 187 
| SUMMARY AND CONCLUSIONS
The proposal that chronic hypoxia as an important driver in the pathogenesis of kidney disease was first developed two decades ago. 4 Since then, much evidence has been produced to show that (i) hypoxia is a common feature of both AKI and CKD, (ii) that at least under in vitro conditions, renal tissue hypoxia drives signalling cascades that lead to tissue damage and dysfunction and that (iii) tissue hypoxia itself can lead to renal pathology, independent of other known risk factors for kidney disease.
There is also some evidence that (iv) tissue hypoxia precedes renal pathology, at least in some forms of AKI and CKD. However, we have made relatively little progress in determining (v) the spatial relationships between tissue hypoxia and pathological processes (i.e. colocalization) or (vi) whether therapies targeted to reduce tissue hypoxia can prevent or delay the progression of renal disease. These questions remain the greatest challenges for the field.
